IL159150A0 - Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket - Google Patents
Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocketInfo
- Publication number
- IL159150A0 IL159150A0 IL15915002A IL15915002A IL159150A0 IL 159150 A0 IL159150 A0 IL 159150A0 IL 15915002 A IL15915002 A IL 15915002A IL 15915002 A IL15915002 A IL 15915002A IL 159150 A0 IL159150 A0 IL 159150A0
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- tad
- hpv
- complex
- binding pocket
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 8
- 239000013078 crystal Substances 0.000 title abstract 2
- 101000742658 Human papillomavirus type 1 Regulatory protein E2 Proteins 0.000 title 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 title 1
- 239000000872 buffer Substances 0.000 abstract 2
- 239000011548 crystallization buffer Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Laminated Bodies (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30441201P | 2001-07-12 | 2001-07-12 | |
| PCT/CA2002/001058 WO2003006495A2 (en) | 2001-07-12 | 2002-07-12 | Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL159150A0 true IL159150A0 (en) | 2004-06-01 |
Family
ID=23176405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15915002A IL159150A0 (en) | 2001-07-12 | 2002-07-12 | Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| IL159150A IL159150A (en) | 2001-07-12 | 2003-12-02 | Human papillomavirus e2 transactivation domain/inhibitor co-crystal and method for its production |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL159150A IL159150A (en) | 2001-07-12 | 2003-12-02 | Human papillomavirus e2 transactivation domain/inhibitor co-crystal and method for its production |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7167801B2 (hu) |
| EP (2) | EP1409525B1 (hu) |
| JP (1) | JP4602665B2 (hu) |
| AT (2) | ATE343588T1 (hu) |
| AU (1) | AU2002317122B2 (hu) |
| CA (1) | CA2448482C (hu) |
| DE (2) | DE60215658T2 (hu) |
| DK (2) | DK1409525T3 (hu) |
| ES (2) | ES2274051T3 (hu) |
| HU (1) | HUP0402069A3 (hu) |
| IL (2) | IL159150A0 (hu) |
| MX (1) | MXPA04000271A (hu) |
| NZ (1) | NZ531068A (hu) |
| WO (1) | WO2003006495A2 (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2565308A1 (en) * | 2003-05-06 | 2004-11-25 | New Century Pharmaceuticals | Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties |
| ATE447610T1 (de) * | 2003-05-26 | 2009-11-15 | Biotie Therapies Corp | Kristalliner vap-1 und verwendung |
| EP1684705A4 (en) * | 2003-11-03 | 2008-02-20 | New Century Pharmaceuticals | ALBUMIN BINDING FACILITIES FOR THE EVALUATION OF MEDICAMENTAL INTERACTION EFFECTS AND METHOD FOR ASSESSING OR DESIGNING MEDICAMENT BASED ON THEIR ALBUMIN BONDING PROPERTIES |
| US20090118301A1 (en) * | 2007-11-02 | 2009-05-07 | Arbor Vita Corporation | Compositions and Methods for Treating Cancer |
| CN112891520A (zh) * | 2021-04-13 | 2021-06-04 | 吉林省国大生物工程有限公司 | 一种预防和控制人乳头瘤病毒感染（hpv）的活性生物蛋白的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07500245A (ja) * | 1991-10-11 | 1995-01-12 | カイロン コーポレーション | パピローマウイルスの複製の阻害剤を同定する方法および組成物 |
| HUP0101396A3 (en) | 1998-05-01 | 2006-03-28 | Boehringer Ingelheim Ca Ltd | Preparation of human papillomavirus e1 having helicase activity and method therefor |
| ATE235509T1 (de) | 1998-06-30 | 2003-04-15 | Deutsches Krebsforsch | Peptide zur inhibition von hpv e7 proteinen |
| WO2000075182A1 (fr) * | 1999-06-04 | 2000-12-14 | Akira Kaji | Cristal de proteine du facteur de recyclage ribosomique (rrf) et son application sur la base de donnees de structure tridimensionnelles provenant du cristal |
| GB9921938D0 (en) | 1999-09-17 | 1999-11-17 | Univ York | Target for antiviral therapy |
| CA2389569A1 (en) * | 1999-11-16 | 2001-05-25 | Vertex Pharmaceuticals Incorporated | Crystallizable compositions comprising a caspase-7 |
| ATE357447T1 (de) | 2000-12-18 | 2007-04-15 | Boehringer Ingelheim Ca Ltd | Inhibitoren des papilloma-virus |
-
2002
- 2002-07-11 US US10/193,460 patent/US7167801B2/en not_active Expired - Lifetime
- 2002-07-12 DE DE60215658T patent/DE60215658T2/de not_active Expired - Lifetime
- 2002-07-12 ES ES02745024T patent/ES2274051T3/es not_active Expired - Lifetime
- 2002-07-12 IL IL15915002A patent/IL159150A0/xx unknown
- 2002-07-12 ES ES06012247T patent/ES2342309T3/es not_active Expired - Lifetime
- 2002-07-12 AU AU2002317122A patent/AU2002317122B2/en not_active Ceased
- 2002-07-12 DE DE60236114T patent/DE60236114D1/de not_active Expired - Lifetime
- 2002-07-12 EP EP02745024A patent/EP1409525B1/en not_active Expired - Lifetime
- 2002-07-12 CA CA2448482A patent/CA2448482C/en not_active Expired - Fee Related
- 2002-07-12 NZ NZ531068A patent/NZ531068A/en not_active IP Right Cessation
- 2002-07-12 JP JP2003512265A patent/JP4602665B2/ja not_active Expired - Fee Related
- 2002-07-12 EP EP06012247A patent/EP1695980B1/en not_active Expired - Lifetime
- 2002-07-12 DK DK02745024T patent/DK1409525T3/da active
- 2002-07-12 AT AT02745024T patent/ATE343588T1/de active
- 2002-07-12 AT AT06012247T patent/ATE465414T1/de active
- 2002-07-12 DK DK06012247.0T patent/DK1695980T3/da active
- 2002-07-12 HU HU0402069A patent/HUP0402069A3/hu unknown
- 2002-07-12 WO PCT/CA2002/001058 patent/WO2003006495A2/en active IP Right Grant
- 2002-07-12 MX MXPA04000271A patent/MXPA04000271A/es active IP Right Grant
-
2003
- 2003-12-02 IL IL159150A patent/IL159150A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60215658T2 (de) | 2007-12-27 |
| MXPA04000271A (es) | 2005-03-07 |
| US7167801B2 (en) | 2007-01-23 |
| ES2274051T3 (es) | 2007-05-16 |
| ES2342309T3 (es) | 2010-07-05 |
| DK1695980T3 (da) | 2010-08-02 |
| JP4602665B2 (ja) | 2010-12-22 |
| ATE343588T1 (de) | 2006-11-15 |
| CA2448482A1 (en) | 2003-01-23 |
| EP1695980B1 (en) | 2010-04-21 |
| EP1695980A3 (en) | 2006-09-06 |
| IL159150A (en) | 2009-09-01 |
| HUP0402069A2 (hu) | 2005-01-28 |
| CA2448482C (en) | 2011-12-06 |
| EP1409525B1 (en) | 2006-10-25 |
| US20030082769A1 (en) | 2003-05-01 |
| DK1409525T3 (da) | 2007-02-05 |
| HUP0402069A3 (en) | 2012-09-28 |
| JP2005512954A (ja) | 2005-05-12 |
| NZ531068A (en) | 2006-06-30 |
| DE60215658D1 (de) | 2006-12-07 |
| WO2003006495A2 (en) | 2003-01-23 |
| EP1409525A2 (en) | 2004-04-21 |
| EP1695980A2 (en) | 2006-08-30 |
| DE60236114D1 (de) | 2010-06-02 |
| AU2002317122B2 (en) | 2007-03-15 |
| WO2003006495A3 (en) | 2003-07-31 |
| ATE465414T1 (de) | 2010-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU662142B2 (en) | Phenyl amidines derivatives useful as platelet aggregation inhibitors | |
| DE50312257D1 (de) | (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure | |
| PL373374A1 (en) | Substituted cycloalkyl p1' hepatitis c virus inhibitors | |
| ATE350338T1 (de) | Chabazit mit hohem gehalt an siliciumdioxid, dessen synthese und verwendung zur umwandlung von sauerstoffverbindungen zu olefinen | |
| AU2003299519A1 (en) | Hepatitis c virus inhibitors | |
| BRPI0410685B8 (pt) | processos de purificação do 1,3-propanodiol e composição | |
| BR9909358A (pt) | Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito | |
| ATE396190T1 (de) | Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase | |
| DK0907639T3 (da) | Polymorfe forbindelser | |
| ATE431340T1 (de) | N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1- piperidincarboxamid-derivate und verwandte verbindungen als cgrp-antagonisten zur behandlung von kopfschmerzen | |
| CY1106721T1 (el) | Μεθοδος παρασκευης υψηλης καθαροτητας περινδοπριλης και ενδιαμεσα χρησιμα στη συνθεση | |
| ATE299029T1 (de) | Verfahren und zusammensetzungen zur peptidsynthese (t-20) | |
| ATE255124T1 (de) | Verfahren zur gewinnung von phytosterinen durch kristallisation aus verminderten mengen methanols | |
| IL159150A0 (en) | Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket | |
| DE59002863D1 (de) | Lysolecithinderivate zur behandlung von autoimmunerkrankungen. | |
| EA200601641A1 (ru) | Кристаллическая композиция, содержащая оксалат эсциталопрама | |
| ATE274513T1 (de) | Verbindungen und verfahren zur behandlung von schmerz | |
| FI972530A0 (fi) | Menetelmä substituoitujen 4-etyyli-piperidiinien valmistamiseksi ja niiden valmistuksessa käytettävä välituote | |
| NZ516235A (en) | Method for purification of proteins | |
| AR015513A1 (es) | Metodo para identificar un compuesto que se asocia con la enzima conversora de alfa-tnf | |
| TR200503398T1 (tr) | Trandolapril'in yeni kristal formları. | |
| ATE174036T1 (de) | Prozess und zwischenverbindungen zur herstellung von blaettchen glycoprotein iib/iiia hemmern | |
| Bach et al. | Expedient Synthesis of 1, 3-Substituted Benzene Peptidomimetics | |
| ANDERSEN et al. | CONFORMATIONAL TRANSITIONS IN DETERGENT TREATED AND MEMBRANE BOUND Ca2+-ATPase FROM SARCOPLASMIC RETICULUM | |
| TH57580B (th) | วิธีการผลิตผลึก |